K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · HARMONY BIOSCIENCES
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-05-04 | HRMY | HARMONY BIOSCIENCES | HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC | $30K | Producing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers. |
| 2026-04-17 | HRMY | HARMONY BIOSCIENCES | LMH STRATEGIC SOLUTIONS | $50K | Healthcare-related legislative and regulatory issues. |
| 2026-04-15 | HRMY | HARMONY BIOSCIENCES | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $50K | Issues related to the development and approval of therapies for rare diseases Pharmaceutical tariffs |
| 2026-04-14 | HRMY | HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $180K | Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies |
| 2026-01-19 | HRMY | HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $180K | S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act |
| 2026-01-16 | HRMY | HARMONY BIOSCIENCES | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $50K | Issues related to the development and approval of therapies for rare diseases Pharmaceutical tarrifs |
| 2026-01-12 | HRMY | HARMONY BIOSCIENCES | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2026-01-06 | HRMY | HARMONY BIOSCIENCES | HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC | $45K | Producing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers. |
| 2025-10-20 | HRMY | HARMONY BIOSCIENCES | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-19 | HRMY | HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $180K | S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act |
| 2025-10-16 | HRMY | HARMONY BIOSCIENCES | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $50K | Issues related to the development and approval of therapies for rare diseases Pharmaceutical tarrifs |
| 2025-10-07 | HRMY | HARMONY BIOSCIENCES | HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC | $45K | Producing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers. |
| 2025-07-21 | HRMY | HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $150K | HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act |
| 2025-07-17 | HRMY | HARMONY BIOSCIENCES | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $50K | Issues related to the development and approval of therapies for rare diseases |
| 2025-07-15 | HRMY | HARMONY BIOSCIENCES | LMH STRATEGIC SOLUTIONS | $0 | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-07-07 | HRMY | HARMONY BIOSCIENCES | HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC | $45K | Producing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers. |
| 2025-04-18 | HRMY | HARMONY BIOSCIENCES | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $50K | Issues related to the development and approval of therapies for rare diseases |
| 2025-04-17 | HRMY | HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $150K | H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress) |
| 2025-04-14 | HRMY | HARMONY BIOSCIENCES | HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC | $45K | Producing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers. |
| 2025-01-20 | HRMY | HARMONY BIOSCIENCES | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $20K | Issues related to the development and approval of therapies for rare diseases |